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You are what you eat, or are you? The challenges of translating
high-fat-fed rodents to human obesity and diabetes
M Lai1,3, PC Chandrasekera1,3 and ND Barnard1,2
Obesity and type 2 diabetes mellitus (T2DM) are rapidly growing worldwide epidemics with major health consequences. Various
human-based studies have confirmed that both genetic and environmental factors (particularly high-caloric diets and sedentary
lifestyle) greatly contribute to human T2DM. Interactions between obesity, insulin resistance and β-cell dysfunction result in human
T2DM, but the mechanisms regulating the interplay among these impairments remain unclear. Rodent models of high-fat diet
(HFD)-induced obesity have been used widely to study human obesity and T2DM. With 49000 publications on PubMed over the
past decade alone, many aspects of rodent T2DM have been elucidated; however, correlation to human obesity/diabetes remains
poor. This review investigates the reasons for this translational discrepancy by critically evaluating rodent HFD models. Dietary
modification in rodents appears to have limited translatable benefit for understanding and treating human obesity and diabetes
due—at least in part—to divergent dietary compositions, species/strain and gender variability, inconsistent disease penetrance,
severity and duration and lack of resemblance to human obesogenic pathophysiology. Therefore future research efforts dedicated
to acquiring translationally relevant data—specifically human data, rather than findings based on rodent studies—would accelerate
our understanding of disease mechanisms and development of therapeutics for human obesity/T2DM.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a rapidly growing global
epidemic affecting4371 million people worldwide.1 In the United
States, 425 million people have diabetes, and it is predicted that
1 in 3 Americans will be diabetic by year 2050.2 Adult-onset T2DM
is a complex multifactorial metabolic disorder influenced by
genetic, lifestyle and environmental risk factors. Impaired glucose
homeostasis in T2DM is primarily characterized by insulin
resistance and β-cell dysfunction culminating in the morbidity
(nephropathy, neuropathy, retinopathy and increased risk of
cardiovascular disease) and mortality. One of the major risk
factors for the development of insulin resistance and subsequent
T2DM is obesity, another epidemic affecting 2.1 billion individuals
worldwide.3 Obese individuals often have excess central visceral
adiposity, a condition that contributes to a chronic increase in
circulating free fatty acids and the resulting metabolites, such as
diacylglycerol and ceramide. These metabolites in turn activate
various signaling cascades that interfere with insulin signaling and
β-cell function, further contributing to the gluco/lipotoxicity.4
Obesity also increases cardiovascular risk factors, such as
dyslipidemia, hypertension and atherosclerosis. Therefore much
of the research efforts over the past two decades have been
dedicated to delineating the etiopathogenic mechanisms of
obesity and diabetes.
A large number of animal models have been generated to study
obesity and diabetes using species ranging from fruit flies to
primates, including dogs, cats, pigs, rabbits, hamsters and squirrels
to common rodent species, rats and mice.5,6 In general, T2DM is
induced in experimental animals by surgical, chemical, dietary and
genetic manipulations as well as combinations thereof. The most
common obese models of T2DM are of spontaneous genetic
origin (for example, naturally occurring mutations in leptin and
leptin receptor)7 or experimentally induced by diet (for example,
prolonged high-fat diet (HFD) feeding).7,8
A simple PubMed database search (using the keywords ‘high fat
diet’ and ‘high fat diet and obesity’ with the filters ‘other animals’
and ‘publication dates’) revealed that 416 000 animal-based HFD
studies have been published to date since the first article
appeared on PubMed in 1964. The trend for animal-based HFD
studies has increased tremendously since then—of the 16 000
papers, 49800 papers were published in the past decade. Despite
the wealth of information obtained from these animal-based HFD
studies, the mechanisms regulating the interplay among obesity,
insulin resistance and β-cell dysfunction in humans remain
unclear. It appears that dietary modification in rodents has limited
translatable benefit for understanding and treating human obesity
and diabetes. The purpose of this review is to investigate the
reasons for this translational discrepancy. This paper also
addresses future directions necessary to conduct transnationally
relevant human obesity and T2DM research.
HFD: DIETARY OPTIONS
The first description of HFD experiments dates back to the early
1940s when rats fed an extreme HFD (70% energy from fat)
developed obesity with elevated basal and postprandial blood
glucose levels.9,10 Another early diet was the ‘cafeteria diet’, a diet
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that included a variety of common, highly palatable human food
that rodents were free to choose from (for example, cheese, ham,
cookies, peanuts, chocolate and cakes).11 The utility of this
cafeteria diet has diminished over the years as it is difficult to
accurately quantify the nutrient intake with substantial variations
in caloric content and types.11,12 Most researchers now use
commercially available predefined HFDs encompassing a wide
range of fat content and types.7 For example, Harlan Laboratories
and Purina TestDiet provide a number of distinct HFD formulas,
where the fat content ranges from 40% to 60%. The fat types
include saturated fatty acids, monosaturated fatty acids, poly-
saturated fatty acids and various combinations thereof, all typically
derived from ingredients such as butter, pork fat, beef tallow, lard
and various oils such as corn, coconut, cottonseed, soybean, olive,
peanut, sesame, cocoa butter and fish oils.13,14
In addition to HFD, high-carbohydrate diets such as high-
fructose and high-sucrose diets are also used to induce features of
the human metabolic syndrome in rodents. High-carbohydrate
diets can be used alone or in combination with a HFD. For
example, a high-sucrose (10–30%) diet can be combined with
high fat (20–40%) to induce metabolic perturbations, such as
increased body weight, abdominal fat deposition, hyperleptine-
mia, hyperinsulinemia, and hyperglycemia.15–17 High-fructose
(10–60%) is combined with high fat (20–60%) to induce the
symptoms such as increased body weight and the plasma
concentrations of cholesterol, triglycerides, free fatty acids and
leptin.16,18,19
HFD-fed rodents are often compared against control-diet-fed
rodents in which a grain-based ‘chow’ diet made primarily from
corn, wheat, oats and soybeans provides basic nutrition.20 Some
researchers have made HFDs by simply adding fat to grain-based
chow, but this chow-based HFD is not recommended as a high
percentage of fat dilutes other ingredients in the diet, thereby
making the diet deficient in micronutrients and macronutrients.7
Given the broad range of dietary modifications now utilized in
obesity and T2DM research, it has not been possible to define the
‘ideal’ HFD nor generate a rodent model that can accurately mimic
the human disease state. As discussed in the following sections,
dietary modification in rodents appears to have limited translat-
ability due—at least in part—to divergent dietary compositions,
species/strain, sex and age variability, inter- and intra-laboratory
variability in disease penetrance, severity and duration and lack of
resemblance to the human obesogenic pathophysiology.
HFD: MAJOR LIMITATIONS TO HUMAN TRANSLATABILITY
HFD-feeding: effect of dietary components
A wide variety of methods are utilized in HFD studies, with no
single method being comparable to the human experience.
A multitude of diets with very different fatty acid compositions are
included under the term ‘high fat diet’, and therefore the resulting
phenotypes also vary considerably. Given the extensive literature
on this topic, only select studies are presented below to illustrate
the variable effects of dietary components and schemes on
glucose regulation. For example, weight gain was reported to
differ significantly between mice fed a HFD consisting of beef fat
versus a HFD of canola oil (138% more weight gain with beef fat
compared with canola oil) despite 40.8% of energy from fat in
both diets.21 In another study, weight gain in mice varied with the
type of fat intake from oils containing different amounts of
palmitic, linoleic and oleic acids: soybean4palm4or = lard4or =
rapeseed4or = safflower4or = perilla4fish oil.22 More recent
studies reiterate that even when protein and carbohydrate ratios
are kept constant, weight gain in the two most commonly used
mouse strains (C57BL/6J and A/J) sharply contrasted between 60%
HFD consisting of 100% saturated fatty acids and a 60% HFD
consisting of 35% saturated, 43.4% monounsaturated and 15.9%
polyunsaturated fatty acids.23 In addition to weight gain, the
resulting metabolic manifestations can also differ with the type
and amount of fat. For example, lard and olive oil have been
shown to cause higher insulin resistance in rodents than coconut
oil and fish oil.7,24 Moreover, despite similar energy intake,
combination diets such as high-fat/high-sucrose diets can exert
differential effects on insulin sensitivity and islet β-cell adaptation
compared with HFD alone.25 Variations in fat-mediated metabolic
perturbations and their impact on rodent studies are discussed in
detail later.
Comparative dietary effects are generally made against chow-
based control diets; however, variations in control diets can
seriously impair data analysis. A study that examined HFD
publications in the year 2007 revealed that only 14% of the
publications made the appropriate comparisons.26 The vast
majority of these studies made conclusions regarding dietary
effects by comparing grain-based chow with a predefined HFD,
neglecting the differences in nutrient content in the two diets,
which can cause unintended but significant metabolic distur-
bances. For example, the type of protein may modulate weight
gain in rodents—rats fed soy diets have less hepatic lipid
deposition, no hyperleptinemia and less overall weight than
those fed casein diets.27 Other ingredients such as fructose can
exacerbate weight gain and isoflavones (phytoestrogens) can
influence fat deposition, plasma insulin, leptin, thyroid, estradiol
and corticosterone levels, lipogenesis and lipolysis in rat
adipocytes as well as consumptive behavior (food and water
intake), learning and memory and anxiety-related behaviors in
rodents.26 These results suggest that the effects of HFD are
confounded by other components present in each diet, further
hindering accurate data interpretation and extrapolation.
Even the standard ‘control’ animals may not be appropriate
controls for obesity research as, in the words of the study author,
these mice kept in controlled environments under a sedentary
lifestyle with continuous access to food are ‘metabolically
morbid… obese, glucose intolerant, and on a trajectory to
premature death’.28 Taken together, due to a broad range of
dietary interventions confounded by other factors affecting overall
metabolism and physiology, it has not been possible to define the
‘ideal’ HFD nor the ideal environment in which to conduct these
experiments. Consequently, results reported among laboratories
are not comparable even among the same species/strain, and
reliable cross-species extrapolation is challenging.
HFD-induced metabolic perturbations: sex, age and strain-
dependence
The commonly reported T2DM-related metabolic perturbations
induced by HFD in rodents include weight gain and increased
carcass lipid content, higher degree of insulin resistance and
increased levels of plasma glucose, insulin, leptin, cholesterol and
triglycerides. However, as discussed below, the development,
severity and duration of these metabolic perturbations are highly
variable due to several factors such as the age at which HFD
feeding starts, duration of HFD feeding, sex and the rodent species
as well as the strain used,29 rendering data analysis and
extrapolation very difficult. Given the breadth of the literature
on this topic, only representative examples are discussed below.
The age of onset and the duration of diet are important
parameters when studying the metabolic syndrome in rodents.
For example, in the most commonly used obesity-prone mouse
strain C57BL/6J, 10-week-old mice displayed smaller increases in
body weight, serum glucose, cholesterol and urea levels and
higher increases in high-density lipoprotein levels than 54-week-
old mice following the identical HFD for 12 weeks.30 When given a
high-fructose or a HFD for 13 weeks, the HFD caused the largest
changes in serum lipids and lipid accumulation in the liver and
kidney in young (4-weeks old) rats, whereas the high-fructose diet
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increased visceral lipid stores, mean arterial pressure and heart
rate in adult (12-weeks old) rats, and the metabolic perturbations
became evident at different stages of the dietary intervention,
suggesting that metabolic effects of diet vary considerably with
age.31 Young mice (6-weeks old) were able to maintain
normoglycemia in response to a HFD by increasing β-cell mass
and β-cell proliferation, whereas older mice (7–8-month old) were
not able to counter-regulate by the same mechanism and became
diabetic.32
The variability of metabolic perturbations among different
rodent strains has been reported since the 1970s. Schemmel
et al.33 found that among seven different rat strains, HFD-induced
weight gain ranged from 50% weight gain in Osborne-Mendel and
Wistar-Lewis rats to 12% weight gain in S5B/P1 males to no weight
gain in S5B/P1 females, indicating both strain- and sex-related
differences. Similarly, the common mouse strains also range
between obesity-prone and obesity-resistant.34 A more in-depth
comparison between the two most common strains of mice
(C57BL/6J and AKR/J) indicated that insulin sensitivity and
regulation of glucose homeostasis differ markedly between these
two strains: C57BL/6J mice display rapid weight gain (14.78 vs
3.74 g in control), hyperglycemia (132 vs 117 mg dl− 1 in control),
and insulin resistance (twofold less sensitive), whereas AKR/J have
increased carcass lipid content (2916 vs 1006 mg in control),
severe impaired glucose tolerance and insulin resistance (5.5-fold
less sensitive) but remained euglycemic (100 vs 96 mg dl− 1 in
control).35 There were no factors that could account for this
greater insulin resistance in AKR/J strain given that non-adipose
tissue triglyceride accumulation was similar in both strains (143 in
C57BL/6J vs 171mg dl− 1 in AKR/J, P40.01).35 Of note, it has been
shown that some strains have higher fasting plasma glucose levels
and lower fasting plasma insulin levels regardless of dietary
content.36 This is not so much an issue considering human T2DM
patients also display a wide range of glucose intolerance and
insulin resistance; however, the major limitation is that these data
are not reproducible among research groups and therefore cannot
be reliably extrapolated across species.
Levin et al.37 reported that, in an outbred adult male Sprague-
Dawley population, weight gain displayed a bimodal distribution
pattern even though the rats were given the same HFD. Only half
the rat population developed obesity, while the remainder
showed no difference from control group. Similarly, female Wistar
rats also showed a bimodal weight gain pattern on a HFD.38 As
both Sprague-Dawley and Wistar rats are outbred strains, one
might argue that the metabolic heterogeneity is due to the ill-
defined genetic nature of outbred colonies.39 However, similar
metabolic variability is also found in C57BL/6J, the most
commonly used inbred mouse strain used for HFD studies.
Burcelin et al.40 found that when C57BL/6J mice were on a HFD for
9 months, the development of obesity and diabetes was not
uniform within the population—both lean and obese phenotypes
developed on the HFD. More strikingly, it was found that mice that
remained lean and non-diabetic after 9 months of HFD feeding
actually had a significantly higher rate of glucose clearance than
those mice in the control group. The wide scattered phenotypic
differences cannot be explained by the variations in genetic
background, because each C57BL/6J mouse has the identical
genetic background. The variability in metabolic perturbations
within a single population compromises any conclusions drawn
from HFD studies, but no solution exists in the research
community to overcome this critical issue.
Some researchers consider the variability among rodent strains
to be similar to the ethnic diversity in the human T2DM
population and argue that multiple phenotypic variations provide
a selection pool for finding suitable models.41 However, in reality,
this variability among strains causes more detriment than
presumed benefit owing to irreproducible results. For example,
even with the same C57BL/6J strain as a comparison baseline,
DBA/2 mice were observed as obesity-prone in one study36 but
obesity-resistant in another.42 Similar discrepancies have been
observed in FVB/N mice as well.43,44 To date, only a few
comprehensive studies using multiple strains have been pub-
lished, and the vast majority of HFD studies are based on a single
strain and single sex. It is unclear whether most researchers select
their ‘most suitable strain’ based on thorough examination of the
phenotypic variations reported. What is clear is that no single
strain can represent a reliable model for human obesity
and T2DM.
HFD-feeding: a comparative analysis of intra- and inter-laboratory
variability
As discussed, HFD-induced metabolic syndrome in rodents is
plagued by many confounding factors, including, but not limited
to, the type of diet (and control diet), duration of exposure to diet,
animal species and strain, age and gender of the animals, and the
clinical manifestations developed and their definitions. Therefore
it is inevitably challenging to find studies suitable for direct
comparison. Nevertheless, it is important to determine whether
HFD data from different laboratories (and within the same
laboratory) can be reliably compared and extrapolated. In this
regard, Table 1 illustrates comparisons made with six studies that
used the same mouse strain, C57BL/6J.23,40,45–48
Among the six studies, the studies of Winzell and Ahren45 and
of Reimer and Ahren47 have the most similar protocols: both
studies used female wild-type C57BL/6J and started HFD at the
age of 4 weeks with the same diet composition. However, even in
studies from the same lab, presumably under the same protocol
(that is, 58% calories from fat), different observations have been
made regarding the development of hyperinsulinemia (see 1 week
versus 8 weeks in Table 1). It is difficult to explain this disparity,
because these two experiments are from the same lab,
presumably with the same protocols, with the only difference
being the duration of study (1 year versus 8 weeks on HFD).
Considering the duration of study, Sone and Kagawa46 conducted
their study for 1 year, which is the same as Winzell and Ahren.45
However, C57BL/6J mice used in the two studies were of different
sexes, age of onset of HFD feeding and diet compositions. The two
studies reported inconsistent results regarding the progression of
weight gain and hypersinsulinemia (Table 1), but it is difficult to
explain the disparity because the two protocols differ in many
aspects except for the duration of study. Considering that dietary
effects vary greatly within species and between closely related
rodent species such as mice and rats, it is challenging to
extrapolate to a distantly related species like Homo sapiens.
In addition to the biological variability, technical variability
inherent in the assays and techniques used for measuring various
parameters of the metabolic syndrome in rodents further
complicates data acquisition, analysis and interpretation. Assays
such as glucose and insulin tolerance tests and hyperglycemic and
hyperinsulinemic–euglycemic clamps have inherent technical
difficulties confounded by procedural factors affecting glucose
metabolism, such as anesthesia, site and volume of blood
sampling, fasting duration and even ambient lighting and time of
day.49 For example, anesthesia can induce hyperglycemia in mice
and influence the assessment of glucose metabolism.50 Tail-bleed
blood sampling of 100 μl can cause stress and lead to increased
catecholamine and basal glucose levels compared with same
volume of artery blood sampling.49 In addition, rodent genetic
background and environmental interactions (for example, housing
facilities) can affect clinical chemical and hematological para-
meters, such as glucose, cholesterol, triglycerides, creatinine, uric
acid, hemoglobin, red and white blood cell counts and platelet
counts.51 Fasting duration, especially an 18-h overnight fast, can
result in the loss of total body, lean and fat masses as well as
hepatic glycogen levels while a 5-h fast can result in increased
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insulin sensitivity.52 In humans, prolonged fasting impairs insulin-
stimulated glucose utilization, but the opposite is true for
rodents.53 Metabolic studies in rodents have shown that changes
to circadian rhythm can also affect glucose metabolism.54 It is
clear that various factors associated with the technical procedures
for assessing glucose metabolism in rodents significantly con-
tribute to inconsistent results, rendering inter-species extrapola-
tion an arduous task.
HFD-feeding: in combination with chemical, surgical and genetic
manipulations
HFD is often used in combination with chemical, surgical and
genetic modes of T2DM induction, but limitations inherent in
these methods have severely restricted the ability to interpret data
in conjunction with HFD feeding. For chemical induction, the
cytotoxic glucose analogs alloxan and streptozotocin are com-
monly used to induce irreversible pancreatic β-cell destruction.55
High-dose streptozotocin destroys most of the endogenous β
cells, thereby decreasing insulin secretion substantially (a condi-
tion similar to T1DM), whereas low-dose streptozotocin induces
mild impairment of insulin secretion (a condition similar to
T2DM).56,57 Chemical induction of a T2DM-like state has its own
disadvantages and combining that with HFD feeding creates
further complications hindering reliable data interpretation and
extrapolation. For example, the dosage and the number of
streptozotocin injections considerably vary among studies: in rats,
dosage can range from 90mg kg− 1 (Eiki et al.58) to 30 mg kg− 1
(Cao et al.59) for single injections while the number of injections
can range from two (Ding et al.60) to four (Li et al.61) with
the dosage ranging from 5mg kg− 1 (Li et al.61) to 30 mg kg− 1
(Zhang et al.62). This in turn leads to highly variable fasting blood
glucose levels (from 5 to 25mmol l− 1), indicating different
degrees of pancreatic β-cell destruction.62 Such discrepancies
make it difficult to compare data even among rodent studies.
In addition, streptozotocin and alloxan can cause extrapancreatic
genotoxic and cytotoxic effects, including the disruption of
the hypothalamic–pituitary–gonadal axis63,64 and changes in
hyperglycemia-unrelated hepatic gene expression,65 making it
difficult to distinguish the effect caused by pancreatic cytotoxicity
from those caused by extrapancreatic sites. The addition of age,
sex and strain-dependent HFD feeding atop already complicated
chemical T2DM induction renders intra- and inter-species extra-
polation impossible.
The most common mode of surgical induction of T2DM is
pancreatectomy, and ventromedial hypothalamus (VMH) lesions
are sometimes used as well. The standard partial (up to 90%) or
complete pancreatectomy often produces non-obese diabetic
models where the extent of pancreatectomy governs the
severity of diabetes.5 Data interpretation and extrapolation
from pancreatectomy models are limited by many confounding
factors. First of all, human T2DM is not caused by a sudden loss
of the pancreas; rather it is actually due to progressive loss of
β-cell function in combination with insulin resistance. Second, in
rodents, pancreatectomy often evokes robust cellular responses
that lead to β-cell regeneration giving full recovery of β-cell
mass even after 40–60% partial pancreatectomy66,67 and up to
200% increase in β-cell number in the pancreatic remnants
following 90% pancreatectomy in rats.68 Unlike in rodents,
partial pancreatectomy does not result in β-cell regeneration in
humans,69 due to differences between human and rodent β-cell
replication mechanisms.70 Although pancreatectomy is a com-
mon surgery used to induce T2DM in rodents, combining it with
HFD only adds to the complexity—removal of the exocrine
pancreas substantially reduces the production of most enzymes
required for intestinal lipid absorption and lipolysis, making it
difficult to obtain reliable results in HFD-fed pancreatectomized
animals.71 These models also lack counter-regulatory mechanisms
imposed by glucagon, thereby adding to the pathophysiological
complexity.
Table 1. Inter- and intra-laboratory variability among six HFD studies using C57BL/6J mouse models




(b) Sone and Kagawa46 (c) Wu et al.48 (d) Gallou-Kabani
et al.23
(e) Burcelin et al.40
Sex Female Female Male Male Both sexes Male
Age of onset of
HFD feeding
4-week old 4-week old 6-week old 8-week old Not specified 4–5-week old
Control diet 11.4% fat 11.4% fat 4% fat 4.3% fat 10% fat 12% fat
HFD: diet 58% fat 58% fat 40% fat 35.2% fat 60% fat 72% fat
HFD: oil Lard Not specified Beef tallow Lard Variousa Corn oil and lard
HFD: duration 1 year 8 weeks 1 year 40 weeks 20 weeks 9 months
Weight gain Weight increased Weight increased Weight loss observed the
last 2 weeks.




1 week on HFD
Hyperglycemia
evolved after
1 week on HFD
Hyperglycemia Mild hyperglycemia.





1 week on HFD
Hyperinsulinemia
developed after
8 weeks on HFD
Hyperinsulinemia at
month 4 but no difference






Abbreviation: HFD, high-fat diet. Wu et al.48 used transgenic C57BL/6J while others used wild-type C57BL/6J. (a) Presumably with the same protocol, Winzell
and Ahren45 observed both hyperglycemia and hyperinsulinemia after 1 week on HFD, in which blood glucose concentration increased by 1.8± 0.2 mmol l− 1
and serum insulin increased by 78± 15 pmol l− 1; both Po0.001. However, Reimer and Ahren47 only observed hyperglycemia after 1 week (increased by
2.1± 0.2 mmol l− 1) as the insulin level dropped from 106± 13 to 71± 6 pmol l− 1 in HFD-fed mice, which did not develop hyperinsulinemia until week 8 on a
HFD (308± 59 pmol l− 1); (b) With the same duration of study, Winzell and Ahren45 reported steady weight gain, hyperglycemia and hyperinsulinemia
progression, while Sone and Kagawa46 reported weight loss at the last 2 weeks, and the progression of hyperinsulinemia stopped near the end of the study;
(c) Wu et al.48 used genetically modified mice (low-density lipoprotein receptor knockouts), and altered genetic background further contributed to the HFD-
induced phenotypic variability; (d) Gallou-Kabani et al.23 used a different protocol and found significant sex-related difference where only male C57BL/6J mice
developed overt type 2 diabetes mellitus but not female C57BL/6J mice; (e) Burcelin et al.40 used yet a different protocol compared with the other studies
discussed here and found the development of obesity and diabetes was not uniform in the population. aVarious: 35.0% of saturated fatty acid, 43.4% of
monounsaturated fatty acids and 15.9% of polyunsaturated fatty acids.
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VMH lesions are generally induced by administration of
monosodium glutamate or direct electrical shock to create
bilateral destruction of the ventromedial and arcuate hypo-
thalamic nuclei. This leads to obesity primarily by hyperphagia
and lack of control between energy absorption and expenditure
governed by leptin, neuropeptide Y and insulin feedback
mechanisms.72 Phenotypic variability in VMH rodent models is
exacerbated by HFD feeding. For example, VMH rats fed the same
HFD develop hyperglycemia at different rates.73 Given the
unnatural induction of hyperglycemic conditions by VMH lesions
and the variable metabolic perturbations present even within a
single rodent strain on a HFD,37 it is difficult to extrapolate these
data to human obesity and diabetes.
HFD is often combined with genetically modified models
(transgenic, knockout, knock-in and overexpression models),
where an overt diabetic phenotype may not appear until obesity
is induced by HFD.74 Regardless of the reason for dietary
modification, genetically modified mice also display age-, sex-
and strain-dependent variability in disease phenotype with or
without HFD induction (Table 2). A prime example of this comes
from knockout mouse models of an islet-enriched zinc transporter,
ZnT8, thought to reside in insulin secretory granules to modulate
proper insulin maturation, storage and secretion. Three indepen-
dent studies published in 2009 alone provided evidence that mice
lacking the gene encoding ZnT8 develop an increased risk for
diabetes; however, there were intriguing differences among these
animal models. As shown on Table 2, these studies reported age-,
sex-, strain- and diet-dependent phenotypic variability (for
example, glucose tolerance, insulin secretion, body weight,
etc.),75–77 even when two colonies of the same ZnT8 null were
maintained in two separate laboratories with the primary
difference being the number of times the knockouts were
backcrossed into C57BL/6J background (three times in the
Toronto, Canada colony and two times in the London, UK
colony).75 Because of the highly variable results observed from
the mixed genetic backgrounds in these studies, another group
later generated ZnT8 knockouts on a pure genetic background
(C57BL6/J) and concluded that ZnT8 does not have a substantial
impact on mouse physiology.78 In addition, even the in vitro
insulin secretion from ZnT8 knockout mouse islets varied from no
effect76 to decreased effect77 to enhanced insulin secretion.75
Furthermore, global knockouts of ZnT8 were shown to be more
susceptible to diet-induced obesity compared with tissue-specific
knockout mice.79 Following all these efforts to generate and
characterize ZnT8 mouse models, a recent study involving 150 000
people carrying ZnT8 mutations revealed that mouse results are
not congruent with the phenotype observed in humans: in
marked contrast to the animal models where gene ablation
resulted in increased risk for T2DM, protein-truncating loss-of-
function mutations actually protect humans from developing
T2DM.80
There are many other examples of highly disparate results
arising from the combination of HFD feeding with genetic
modification. For example, loss of GPR40 (a G-protein-coupled
receptor expressed predominantly in pancreatic islets mediating
free fatty acid-induced insulin secretion) protects mice from HFD-
induced diabetes,81 whereas the same gene ablation fails to
protect mice from HFD-induced diabetes in another study.82
Although disparity in GPR40 studies arose on a C57BL/6J
background, metabolic phenotypes appear to differ between
strains of transgenic/knockout mice with identical genetic
mutations (for example, insulin receptor and insulin receptor
substrate-1 knockout mice).83,84 When HFD is combined with
genetic modification in both sexes, the disparate phenotypes seen
in males and females have forced studies to draw conclusions
mainly from one sex85–88—many HFD studies only include one sex
in their experiments to avoid sex-related differences. There have
even been instances where effects of a HFD diminished with time,
as has been shown for low-density lipoprotein receptor knockout
mice on a C57BL/6J background who lost their lard-based HFD-
induced mild hyperglycemia after 40 weeks.48 This is rather
unexpected as C57BL/6J is reported to develop more severe
metabolic disturbances over other strains, such as AKR/J and A/J
mice.35 These studies beg the question, if a model using one
rodent age, sex, strain and diet type cannot be extrapolated to
another cohort of the same species, how much confidence can
there be in extrapolating across the species barrier to humans?
In addition to the effect of dietary modification, primary and
secondary effects of the genetic manipulation itself may heavily
influence the observed phenotype. For example, genetic manip-
ulation does not result in an observable phenotype due to the
presence of compensatory mechanisms (for example, SUR1
knockout mice), or presents a more exaggerated phenotype than
what may be present in the polygenic T2DM state (for example,
glucose transporter 2 null mice).70 Gene inactivation is effective
throughout development, and therefore it is difficult to distinguish
phenotypes arising from developmental defects from those
directly resulting from impaired glucose homeostasis. Without
the ability to confidently differentiate between knockout effect,
compensatory effect and developmental effects, genetically
manipulated models offer limited value when combined with
HFD feeding, where all of these issues are further exacerbated by
HFD-dependent sex, age and strain variability. Taken together,
HFD feeding with chemical, surgical and genetic manipulation
further limits the ability of rodent models to accurately mimic
human obesity and diabetes.
HFD-induced obesity and diabetes in rodents: relevance to human
pathophysiology
In order for a rodent model to have relevance to human disease, it
should effectively recapitulate the natural history, pathophysiology
and complications in a manner similar to what is observed in
humans. However, this does not appear to be the case for HFD-fed
rodents trying to mimic human obesity and diabetes. First of all,
the large number of diets used for HFD studies in rodents may not
appropriately represent the general human diet, particularly the
‘obesogenic’ Western diet. For example, the US population on
average consumes 30–40% dietary fat regardless of weight
(whether normal, overweight or obese).89,90 Therefore, using
40–60% fat (that is, values significantly 440%) in rodent dietary
interventions is too extreme compared with the average Western
diet. Moreover, human diets are much more complex than the
carefully formulated rodent HFDs. According to the US National
Cancer Institute, human foods and beverages can be divided into
97 categories, such as grain-based desserts, pasta and pasta
dishes, beef and beef-mixed dishes and so on, with many
subcategories.91 Humans also consume alcohol and excessive
sodium, which are not found in rodent feed, but affect human
pathophysiology. Therefore rodent diets differ from the diet
that lead to human obesity and diabetes and associated
complications.16
Apart from the actual diet, consumptive behavior also differs
between rodents and humans. Humans tend to have stress,
emotions and cultural factors that affect their access to food,
selection of diet and feeding behavior.92 For example, uncon-
trolled food intake can lead to overeating due to complex
psychological factors in humans,93 which cannot be accurately
mimicked in rodent models. In some rodent models, disruption of
leptin signaling is the primary cause of hyperphagia rather than
feeding behavior governed by emotional factors. Furthermore,
unlike humans, mice consume most of their food at night.94 As a
result, the routine overnight fasting of 16–18 h is an unhealthy
long period of time that provokes a catabolic state capable of
nearly depleting liver glycogen stores, a state more akin to
starvation in mice.95 In lean mice, overnight fasting can reduce
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lean body mass by ∼ 15%.52 In addition, prolonged fasting in mice
enhances insulin-stimulated glucose utilization, whereas it is
impaired in humans.49 Moreover, mice can undergo reduced
metabolic rate (physiological state of torpor), whereas humans
cannot.94
These metabolic stresses are further exacerbated by the
ambient temperature in general laboratory housing (18–22 °C),
which is well below their critical thermoneutrality point of ~ 30 °C.
This chronic thermal stress causes mice to increase their
metabolism by increasing food intake by as much as 50%,96–99
further skewing data. Controlled light/dark cycles adapted for
human convenience (that is, typical 0800–1700 work hours) could
have negative influences on mouse physiology, as changes to
circadian rhythms can affect glucose metabolism.49 In general,
rodents have higher metabolic rates governed by much higher
heart rates ranging from 350 to 550 beats min− 1, whereas humans
have lower metabolic rates accompanied by lower heart rates
around 70 beats min− 1.
Translatable rodent models of T2DM should accurately mirror
the etiopathology of the human condition; however, this is rarely
the case with the vast majority of rodent models, including HFD
models. In humans, a complex genetic background interacts with
environmental factors leading to progressive disease develop-
ment, which occurs over a long period of time on the order of
years to decades.100 In contrast, most rodent HFD studies last only
a few weeks (and a few months at most) as rodents can develop
obesity and insulin resistance after 2 weeks on a HFD, albeit to
varying degrees.7 Because of rapid unnatural disease induction,
HFD models often lack (or incorrectly mimic) T2DM-associated
vascular complications, which develop over many years, usually
starting long before the clinical diagnosis of overt hyperglycemia
in humans. Macrovascular complications (primarily described as
cardiovascular complications) are the leading cause of morbidity
and mortality, which occur predominantly via accelerated athero-
sclerosis in humans. By contrast, rodents show resistance to high
low-density lipoprotein cholesterol, atherosclerosis, platelet aggre-
gation and hypertension.70 In a study examining the association
between atherosclerosis and T2DM in a HFD rodent model, no
difference exists between the control and the HFD group in all
indicators of atherosclerosis despite the presence of metabolic
perturbations such as hyperinsulinemia, hyperglycemia and
obesity.48
Table 2. Variability among studies in which genetic modification is combined with HFD
Genetic model Experimental findings
ZnT8− /− : Colony derived in France on a mixed
129SeVe/C57BL/6J background and maintained
in Toronto and London75
Age- and sex-dependence: in the Toronto colony, elevated FPG and GI in male mice at 6 weeks of
age, but not at 12 weeks; normal FPG, but GI at both ages in females; in the London colony, male
mice had GI at both ages, but female mice had normal glucose tolerance at 12 weeks
Strain-dependence: mixed 129SvEv/C57BL/6J background; Toronto colony was backcrossed 3 ×
and the London colony was backcrossed 2× on to C57BL/6J (possible explanation for age- and
sex-dependence)
Diet-dependence: HFD increased body weight in ZnT8− /− compared with wild type; increased
fasting plasma insulin levels
In vitro: increased basal insulin release in ZnT8− /− islets
ZnT8− /− : Colony derived in France on a mixed
129SeVe/C57BL/6J background and maintained
in Leuven76
Age-dependence: FPG and insulin levels unchanged at ages 6, 12, 25 weeks and 1 year. No
difference in insulin sensitivity at 12 weeks
Sex-dependence: No apparent sex differences; only slight (but statistically significant) change in
glucose tolerance at 6 weeks in female ZnT8− /−
Strain-dependence: mixed 129SvEv/C57BL/6J background; overall metabolic abnormalities mild
compared with Nicolson et al.75
Diet-dependence: normal glucose tolerance on standard diet; HFD increased body weight by
10%; mild GI at 10 weeks on HFD; overt diabetes (blood glucose414mM) in 50% of ZnT8− /−
In vitro: no change in glucose-induced insulin secretion in ZnT8 knockout islets
ZnT8− /− : Mixed 129SeVe/ C57BL/6J
background77
Age-dependence: no change in body weight; blood glucose unchanged at 16 weeks of age
Sex-dependence: compared with females, metabolic parameters such as plasma insulin, glucose,
triglycerides and cholesterol levels were higher in males, but glucagon levels were lower in males
Strain-dependence: mixed 129SeVeBrd/ C57BL/6J background; FPG unaltered; decreased insulin
levels; no impairment in glucose clearance; overall mild metabolic phenotype
Diet-dependence: experiments conducted only on standard control diet
In vitro: glucose-induced insulin secretion markedly decreased in ZnT8 knockout islets
ZnT8− /− : Pure C57BL/6J background78 Age-dependence: normal glucose tolerance at ~ 20–22 weeks, but a small impairment in glucose
tolerance in younger (~4 weeks old) male mice; HFD studied only at 40–50 weeks of age
Sex-dependence: normal fasting insulin levels in males; reduced fasting plasma insulin levels,
but no change in FPG levels in females
Strain-dependence: pure C57BL/6J background; no change in glucose tolerance; female
phenotype appears to be less dependent on 129SvEv-specific modifier genes while male
phenotype appears to be heavily influenced by 129SvEv-specific modifier genes
Diet-dependence: decreased plasma insulin levels in males; no diabetic phenotype—40–50-
week-old mice protected from HFD-induced obesity
In vitro: no change in glucose-induced insulin secretion
ZnT8− /− : Mixed 129SeVe/ C57BL/6J
backcrossed 6 times onto C57BL/6J79
Global and β-cell-specific deletions of ZnT8—global knockouts more susceptible to HFD-induced
obesity compared with tissue-specific knockouts. Global knockouts became obese,
hyperglycemic, hyperinsulinemic, insulin resistant and glucose intolerant compared with
littermate controls; in contrast, β-cell-knockouts had impaired glucose tolerance, though similar
body weights, compared with littermate controls
Abbreviations: FPG, fasting plasma glucose; GI, glucose intolerance; HFD, high-fat diet; ZnT8− /− , homozygous knockout of zinc transporter type 8 encoded
by Slc30A8 gene. This table summarizes a representative example of the variability commonly found in studies in which a genetic manipulation is combined
with HFD feeding. Although there are many other studies that would fit these criteria, due to length limitations, only select examples are described in this
review.
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The main microvascular complications that occur in humans are
nephropathy, neuropathy and retinopathy; however, reliable
rodent models that can effectively recapitulate these human
complications are still lacking, especially with HFD-induced
models. For example, advanced proliferative diabetic retinopathy
characterized by intravetreal neovascularization—the leading
clinical feature causing blindness in humans worldwide—has
not been successfully displayed in a single animal model of T2DM,
much less HFD-fed rodents.101 For diabetic nephropathy, only
early signs of renal damage are usually observed even in the long-
term diet-induced models of T2DM.102 In terms of diabetic
neuropathy, rodents may develop some peripheral nerve func-
tional abnormalities but do not develop structural abnormalities
seen with human diabetic neuropathy.70,103,104 Taken together,
HFD rodent models display variable and partial features, often
resembling only the early stages of human vascular complications.
Therefore, these models have limited translatable benefit, and
overestimation of these data can lead to inaccurate delineation of
disease mechanisms in humans. Furthermore, drugs tested to be
effective in models displaying only early signs of vascular
complications may not work as effectively for the general human
population that routinely manifests advanced disease phenotypes.
It appears that even functional genomics may not be reliably
translated from HFD models to the human state. In a functional
genomics study, comparing differential gene expressions in HFD
rats and obese humans indicated that there is only minimal
overlap of the differentially expressed genes between the HFD
versus control rats and obese versus non-obese human compar-
isons. The study found that genes in both fatty acid metabolism
and oxidation showed different regulation patterns between
obese human and rats.105 The discrepancies in differential gene
expression between HFD rats and obese humans, especially in the
metabolic pathways, further decrease the applicability of HFD
rodent models to human obesity and T2DM research. In addition,
species differences at every level of glucose regulation (from gene
expression to the maintenance of whole-body glucose home-
ostasis) further restrict the ability to extrapolate data from rodent
HFD models to human obesity and diabetes.70
SUMMARY AND FUTURE PERSPECTIVES
A combination of several techniques has enabled the creation of a
large number of animal models with varying obesogenic/
diabetogenic phonotypes. However, it is clear that the natural
history and metabolic characteristics of the human condition
cannot be effectively recapitulated in a single model or even a
combination of these animal models. Induction of T2DM-like
features with HFD feeding is very common in research, but major
limitations significantly reduce the translatability of rodent-based
dietary intervention data to human disease mechanisms and
treatment options. Despite the current literature describing many
thousands of diet-induced rodent studies, the question of which
HFD is best to model the metabolic syndrome seen with human
obesity still remains unanswered. Based on this body of literature
that provides ample evidence showing even the same rodent
(for example, Sprague-Dawley rat) from three different vendors
(for example, Harlan, Charles River and Simonsen) can display
substantial phenotypic differences with respect to metabolism,106
it is not possible to define a recipe for the ‘ideal’ HFD, dietary
components and control diet capable of yielding the best and
most reproducible results in rodents, nor the characterization of
metabolic perturbations based on an exact dietary composition,
duration of diet and age of onset of diet due to many
confounding factors such as species, strain, age, sex, housing
environment and husbandry practices and biochemical/physiolo-
gical assessment techniques (Figure 1). Moreover, animal studies
are biased with respect to experimental design and data
reporting, with excess significance and overoptimistic translational
efficacy widely reported in the literature.107,108 Specious extra-
polations and overstated significance of rodent studies have
hindered the outcome of human therapeutics. Consequently, only
a few anti-diabetic drugs are currently available on the market
despite the substantial amount of information acquired thus far
from animal studies of obesity and diabetes.70 It seems clear that
research efforts must be redirected to studying human T2DM
using human-based methods in order to acquire human-relevant
information.
The limitations of animal models suggest the value of studying
human glucose biology directly. Obesity and T2DM can be studied
from gene expression to whole-animal physiology to environ-
mental level using human-based methods.70 Utilization of a broad
range of human-based methods would enable the researcher to
reliably capture the whole spectrum of the polygenic, multi-
factorial human metabolic syndrome and T2DM. Acute and long-
term effects of diet composition can be directly studied in humans
on a specific dietary regime. For example, the identity of the
molecular defect(s) underlying obesity-induced insulin resistance
can be studied from skeletal muscle biopsy samples, and whole-
body insulin sensitivity can be studied via hyperinsulinemic–
euglycemic clamp from human subjects on a given dietary
regime.109,110 Proteomic analysis of human skeletal muscle111
presents a dynamic pattern of protein abundance in insulin
Figure 1. Primary factors contributing to the variability observed in
HFD-fed rodent models. Variability observed within and among
laboratories using HFD-based rodent models can be broadly
classified into biological, dietary and experimental variability
primarily arising from factors such as species, strain, sex, age, HFD
fat content and type, other dietary components, control diet and
duration of HFD feeding. This variability is further exacerbated when
combined with chemical, surgical and genetic manipulations as
well as physiological and environmental factors affecting data
acquisition.
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resistance, serving as a basis of novel hypothesis testing for
molecular mechanistic studies.
Understanding disease etiopathogenesis is crucial for the
development of new therapeutic interventions, but human
environmental influence on disease ontogeny cannot be recre-
ated in a laboratory setting nor can they exert the same effect on
another species. Therefore studies in epigenome-wide DNA
methylation profiling of pancreatic islets can help link epigenetics
to T2DM and identify differential methylation in several T2DM-
associated genes.112 A number of human epidemiological studies
have resulted in the identification of dietary risk factors in various
human populations, such as Pima Indians, Chinese and other
ethnic groups.113–117 Recent studies have shown that diet and
obesity may even have a microbial component. For example,
intestinal microbiome gene profile has been shown to differ
between lean and obese individuals on different diets,118 and the
human gut microbial profile has been linked to human insulin
action.119 Given that diet can modify factors like gut microbiota
and subsequent influence on host metabolism, it is crucial to
obtain data directly relevant to the human species, as such factors
can differ significantly between rodents and humans. Further
refinement of existing methods and the development of novel
human-based research methods will transform obesity and T2DM
research in a human-relevant manner.
Dietary modification in rodent models has limited translatable
benefit for understanding the pathogenesis of human obesity and
diabetes. The information obtained from the HFD studies are often
confined to the species and strain, and even to simply one sex,
rather than being applicable to the human disease state. It is,
therefore, necessary to dedicate future research efforts to
obtaining transnationally relevant data, specifically human data,
rather than findings based on rodent studies. Redirecting
biomedical research back to humans is clearly the way to
efficiently deal with the current obesity and diabetes epidemics.
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